Table 1.
Transplant characteristic of the patients.
| Total patients (n=162) | |
|---|---|
| Males | 95 (58.6%) |
| Females | 67 (41.4%) |
| Average Age (years, range) | 27.8 (2–68) |
| Median hospital stay (days, range) | 33 (17–56) |
| Type of transplant | |
| Autologous | 38 (23.5%) |
| Allogeneic | 124 (76.5%) |
| Sibling matched related | 110 (88.7%) |
| Haplo-identical | 6 (4.8%) |
| Matched unrelated | 8 (6.4%) |
| Hematological diagnosis | |
| Thalassemia Major | 51 (31.5%) |
| Acute Myeloid Leukemia | 24 (14.8%) |
| Acute Lymphoblastic Leukemia | 12 (7.4%) |
| Severe Aplastic Anemia | 25 (15.4%) |
| Multiple Myeloma | 22 (13.6%) |
| Non-Hodgkin Lymphoma | 10 (6.17%) |
| Hodgkin Lymphoma | 7 (4.3%) |
| Others | 11 (6.8%) |
| Conditioning regimen | |
| Busulfan/Cyclophosphamide/±ATG | 51 (31.5%) |
| Fludarabine/Cyclophosphamide/±ATG | 27 (16.6%) |
| Fludarabine/Melphalan | 20 (12.3%) |
| Treosulphan/Thiotepa/Fludarabine | 27 (16.6%) |
| Melphalan | 22 (13.6%) |
| Carmustine/Etoposide/Cytarabine/Melphalan | 15 (9.3%) |
| Acute GVHD | |
| Grade I | 11 |
| Grade II–IV | 12* |
*
Patients who developed GVHD before discharge; Patients who developed GVHD after discharge are not included.